Jean Christopher Chamcheu1, Vaqar M Adhami1, Stephane Esnault2, Mario Sechi3, Imtiaz A Siddiqui1, Kenneth A Satyshur4,5, Deeba N Syed1, Shah-Jahan M Dodwad1, Maria-Ines Chaves-Rodriquez1,6, B Jack Longley1, Gary S Wood1, Hasan Mukhtar1. 1. 1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin. 2. 2 Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin. 3. 3 Department of Chemistry and Pharmacy, University of Sassari , Sassari, Italy . 4. 4 Small Molecule Screening Facility, Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin. 5. 5 Middleton VA Medical Center , Madison, Wisconsin. 6. 6 Centro de Investigación en Biotecnología Instituto Tecnológico de Costa Rica , Cartago, Republica de Costa Rica.
Abstract
AIM: The treatment of psoriasis remains elusive, underscoring the need for identifying novel disease targets and mechanism-based therapeutic approaches. We recently reported that the PI3K/Akt/mTOR pathway that is frequently deregulated in many malignancies is also clinically relevant for psoriasis. We also provided rationale for developing delphinidin (Del), a dietary antioxidant for the management of psoriasis. This study utilized high-throughput biophysical and biochemical approaches and in vitro and in vivo models to identify molecular targets regulated by Del in psoriasis. RESULTS: A kinome-level screen and Kds analyses against a panel of 102 human kinase targets showed that Del binds to three lipid (PIK3CG, PIK3C2B, and PIK3CA) and six serine/threonine (PIM1, PIM3, mTOR, S6K1, PLK2, and AURKB) kinases, five of which belong to the PI3K/Akt/mTOR pathway. Surface plasmon resonance and in silico molecular modeling corroborated Del's direct interactions with three PI3Ks (α/c2β/γ), mTOR, and p70S6K. Del treatment of interleukin-22 or TPA-stimulated normal human epidermal keratinocytes (NHEKs) significantly inhibited proliferation, activation of PI3K/Akt/mTOR components, and secretion of proinflammatory cytokines and chemokines. To establish the in vivo relevance of these findings, an imiquimod (IMQ)-induced Balb/c mouse psoriasis-like skin model was employed. Topical treatment of Del significantly decreased (i) hyperproliferation and epidermal thickness, (ii) skin infiltration by immune cells, (iii) psoriasis-related cytokines/chemokines, (iv) PI3K/Akt/mTOR pathway activation, and (v) increased differentiation when compared with controls. Innovation and Conclusion: Our observation that Del inhibits key kinases involved in psoriasis pathogenesis and alleviates IMQ-induced murine psoriasis-like disease suggests a novel PI3K/AKT/mTOR pathway modulator that could be developed to treat psoriasis. Antioxid. Redox Signal. 26, 49-69.
AIM: The treatment of psoriasis remains elusive, underscoring the need for identifying novel disease targets and mechanism-based therapeutic approaches. We recently reported that the PI3K/Akt/mTOR pathway that is frequently deregulated in many malignancies is also clinically relevant for psoriasis. We also provided rationale for developing delphinidin (Del), a dietary antioxidant for the management of psoriasis. This study utilized high-throughput biophysical and biochemical approaches and in vitro and in vivo models to identify molecular targets regulated by Del in psoriasis. RESULTS: A kinome-level screen and Kds analyses against a panel of 102 human kinase targets showed that Del binds to three lipid (PIK3CG, PIK3C2B, and PIK3CA) and six serine/threonine (PIM1, PIM3, mTOR, S6K1, PLK2, and AURKB) kinases, five of which belong to the PI3K/Akt/mTOR pathway. Surface plasmon resonance and in silico molecular modeling corroborated Del's direct interactions with three PI3Ks (α/c2β/γ), mTOR, and p70S6K. Del treatment of interleukin-22 or TPA-stimulated normal human epidermal keratinocytes (NHEKs) significantly inhibited proliferation, activation of PI3K/Akt/mTOR components, and secretion of proinflammatory cytokines and chemokines. To establish the in vivo relevance of these findings, an imiquimod (IMQ)-induced Balb/c mousepsoriasis-like skin model was employed. Topical treatment of Del significantly decreased (i) hyperproliferation and epidermal thickness, (ii) skin infiltration by immune cells, (iii) psoriasis-related cytokines/chemokines, (iv) PI3K/Akt/mTOR pathway activation, and (v) increased differentiation when compared with controls. Innovation and Conclusion: Our observation that Del inhibits key kinases involved in psoriasis pathogenesis and alleviates IMQ-induced murinepsoriasis-like disease suggests a novel PI3K/AKT/mTOR pathway modulator that could be developed to treat psoriasis. Antioxid. Redox Signal. 26, 49-69.
Entities:
Keywords:
antioxidants; delphinidin; imiquimod model of inflammation; psoriasis
Authors: Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar Journal: Nat Biotechnol Date: 2011-10-30 Impact factor: 54.908
Authors: Michel Gilliet; Curdin Conrad; Michael Geiges; Antonio Cozzio; Wolfgang Thürlimann; Günter Burg; Frank O Nestle; Reinhard Dummer Journal: Arch Dermatol Date: 2004-12
Authors: Pascal Furet; Vito Guagnano; Robin A Fairhurst; Patricia Imbach-Weese; Ian Bruce; Mark Knapp; Christine Fritsch; Francesca Blasco; Joachim Blanz; Reiner Aichholz; Jacques Hamon; Doriano Fabbro; Giorgio Caravatti Journal: Bioorg Med Chem Lett Date: 2013-05-14 Impact factor: 2.823
Authors: M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Heloisa P Soares; Ming Ming; Michelle Mellon; Steven H Young; Liang Han; James Sinnet-Smith; Enrique Rozengurt Journal: Mol Cancer Ther Date: 2015-02-11 Impact factor: 6.261
Authors: Christine C Milburn; Maria Deak; Sharon M Kelly; Nick C Price; Dario R Alessi; Daan M F Van Aalten Journal: Biochem J Date: 2003-11-01 Impact factor: 3.857
Authors: S-J Chen; T Nakahara; M Takahara; M Kido; L Dugu; H Uchi; S Takeuchi; Y-T Tu; Y Moroi; M Furue Journal: Br J Dermatol Date: 2008-10-25 Impact factor: 9.302
Authors: Ksenija Bernau; Jonathan P Leet; Stephane Esnault; Andrea L Noll; Michael D Evans; Nizar N Jarjour; Nathan Sandbo Journal: J Allergy Clin Immunol Date: 2018-06-21 Impact factor: 10.793
Authors: Amitis Karrys; Islam Rady; Roxane-Cherille N Chamcheu; Marya S Sabir; Sanchita Mallick; Jean Christopher Chamcheu; Peter W Jurutka; Mark R Haussler; G Kerr Whitfield Journal: Nutrients Date: 2018-02-04 Impact factor: 5.717
Authors: Jean Christopher Chamcheu; Islam Rady; Roxane-Cherille N Chamcheu; Abu Bakar Siddique; Melissa B Bloch; Sergette Banang Mbeumi; Abiola S Babatunde; Mohammad B Uddin; Felicite K Noubissi; Peter W Jurutka; Yong-Yu Liu; Vladimir S Spiegelman; G Kerr Whitfield; Khalid A El Sayed Journal: Int J Mol Sci Date: 2018-06-16 Impact factor: 5.923
Authors: Laura Mercurio; Martina Morelli; Claudia Scarponi; Elan Z Eisenmesser; Nunzianna Doti; Gianluca Pagnanelli; Emanuela Gubinelli; Cinzia Mazzanti; Andrea Cavani; Menotti Ruvo; Charles A Dinarello; Cristina Albanesi; Stefania Madonna Journal: Cell Death Dis Date: 2018-10-30 Impact factor: 8.469
Authors: Jean Christopher Chamcheu; Imtiaz A Siddiqui; Vaqar M Adhami; Stephane Esnault; Dhruba J Bharali; Abiola S Babatunde; Stephanie Adame; Randall J Massey; Gary S Wood; B Jack Longley; Shaker A Mousa; Hasan Mukhtar Journal: Int J Nanomedicine Date: 2018-07-20